Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats

Hypertension Research

Volumn 31, Issue 3, 2008, Pages 525-533

  Guo, Qi ^a   Minami, Naoyoshi ^a   Mori, Nobuyoshi ^a   Nagasaka, Makoto ^a   Ito, Osamu ^a   Kurosawa, Hajime ^a   Kanazawa, Masayuki ^a   Kohzuki, Masahiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Calcium channel blocker; Exercise; Insulin sensitivity; Sympathetic nerve activity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; INSULIN; OLMESARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL COUNT; CELL TYPE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; EXERCISE; GLUCOSE CLAMP TECHNIQUE; INSULIN SENSITIVITY; MALE; MONOTHERAPY; MUSCLE CELL; NONHUMAN; OUTCOME ASSESSMENT; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; COMBINED MODALITY THERAPY; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEART RATE; HYPERTENSION; IMIDAZOLES; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, INBRED SHR; REGRESSION ANALYSIS; SYMPATHETIC NERVOUS SYSTEM; TETRAZOLES;

EID: 42649142646     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.525     Document Type: Article

References (44)

1. Natali A, Santoro D, Palombo C, et al: Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17: 170-178.
2. Melancon S, Bachelard H, Badeau M, et al: Effects of high-sucrose feeding on insulin resistance and hemodynamic responses to insulin in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 290: H2571-H2581.
3. Hedman A, Reneland R, Lithell HO: Alterations in skeletal muscle morphology in glucose-tolerant elderly hypertensive men: relationship to development of hypertension and heart rate. J Hypertens 2000; 18: 559-565.
4. Frisk-Holmberg M, Essen B, Fredrikson M, Strom G, Wibell L: Muscle fibre composition in relation to blood pressure response to isometric exercise in normotensive and hypertensive subjects. Acta Med Scand 1983; 213: 21-26.
5. Prewitt RL, Chen II, Dowell R: Development of microvascular rarefaction in the spontaneously hypertensive rat. Am J Physiol 1982; 243: H243-H251.
6. Ben Bachir-Lamrini L. Sempore B, Mayet MH, Favier RJ: Evidence of a slow-to-fast fiber type transition in skeletal muscle from spontaneously hypertensive rats. Am J Physiol 1990; 258: R352-R357.
7. Arauz-Pacheco C, Lender D, Snell PG, et al: Relationship between insulin sensitivity, hyperinsulinemia, and insulin-mediated sympathetic activation in normotensive and hypertensive subjects. Am J Hypertens 1996; 9: 1172-1178.
8. Scherrer U, Sartori C: Insulin as a vascular and sympatho-excitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
9. Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-209.
10. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S: Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens Res 2003; 26: 383-387.
11. Tomiyama H, Yambe M, Yamada J, et al: Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. J Hypertens 2007; 25: 883-889.
12. Kihara A: Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion. Am Heart J 1991; 122: 363-369.
13. Lind L, Berne C, Pollare T, Lithell H: Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995; 9: 137-141.
14. Moan A, Hoieggen A, Seljeflot I, et al: The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-1097.
15. Kohno K, Matsuoka H, Takenaka K, et al: Renal depressor mechanisms of physical training in patients with essential hypertension. Am J Hypertens 1997; 10: 859-868.
16. Minami N, Mori N, Nagasaka M, et al: Mechanism behind augmentation in baroreflex sensitivity after acute exercise in spontaneously hypertensive rats. Hypertens Res 2006; 29: 117-122.
17. Brown DR, Brown LV, Patwardhan A, Randall DC: Sympathetic activity and blood pressure are tightly coupled at 0.4 Hz in conscious rats. Am J Physiol 1994; 267: R1378-R1384.
18. Takada M, Ura N, Higashiura K, et al: Effects of cilnidipine on muscle fiber composition, capillary density and muscle blood flow in fructose-fed rats. Hypertens Res 2001; 24: 565-572.
19. Kawamura T, Yoshida K, Sugawara A, et al: Regulation of skeletal muscle peroxisome proliferator-detivated receptor gamma expression by exercise and angiotensin-converting enzyme inhibition in fructose-fed hypertensive rats. Hypertens Res 2004; 27: 61-70.
20. Grim M, Carlson BM: Alkaline phosphatase and dipeptidylpeptidase IV staining of tissue components of skeletal muscle: a comparative study. J Histochem Cytochem 1990; 38: 1907-1912.
21. Cabassi A, Vinci S, Cantoni AM, et al: Sympathetic activation in adipose tissue and skeletal muscle of hypertensive rats. Hypertension 2002; 39: 656-661.
22. Julius S, Gudbrandsson T, Jamerson K, Tariq Shabab S, Andersson O: The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-986.
23. Deibert DC, DeFronzo RA: Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65: 717-721.
24. McCarty MF: Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. Med Hypotheses 2004; 62: 830-838.
25. Nowak L, Adamczak M, Wiecek A: Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005; 18: 1470-1475.
26. Trayhurn P, Duncan JS, Hoggard N, Rayner DV: Regulation of leptin production: a dominant role for the sympathetic nervous system? Proc Nutr Soc 1998; 57: 413-419.
27. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
28. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P: Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens 2007; 25: 169-175.
29. Shokoji T, Fujisawa Y, Kiyomoto H, et al: Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005; 28: 1017-1023.
30. Kimura Y, Hirooka Y, Sagara Y, Sunagawa K: Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens 2007; 29: 13-21.
31. Nap A, Balt JC, Pfaffendorf M, Van Zwieten PA: Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta. J Hypertens 2002; 20: 1821-1828.
32. Kamide K, Rakugi H, Higaki J, et al: The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 2002; 15: 66-71.
33. Laterza MC, de Matos LD, Trombetta IC, et al: Exercise training restores baroreflex sensitivity in never-treated hypertensive patients. Hypertension 2007; 49: 1298-1306.
34. Hudlicka O: Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation? Microcirculation 1998; 5: 5-23.
35. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-H1019.
36. Kitayama H, Maeshima Y, Takazawa Y, et al: Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006; 19: 718-727.
37. Scheidegger KJ, Nelissen-Vrancken MH, Leenders PJ, et al: Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system. J Hypertens 1997; 15: 1455-1462.
38. Melo RM, Martinho E Jr, Michelini LC: Training-induced, pressure-lowering effect in SHR: wide effects on circulatory profile of exercised and nonexercised muscles. Hypertension 2003; 42: 851-857.
39. James DE, Jenkins AB, Kraegen EW: Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. Am J Physiol 1985; 248: E567-E574.
40. Higashiura K, Ura N, Takada T, et al: The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000; 13: 290-297.
41. Lin J, Wu H, Tarr PT, et al: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797-801.
42. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
43. Oizumi K, Nishino H, Miyake S, et al: Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR. Jpn J Pharmacol 1990; 54: 1-6.
44. Nakamoto M, Ohya Y, Sakima A, Yamazato M, Takishita S: Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats. Hypertens Res 2007; 30: 359-366.